Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dr. Uhre et al. Reply

    Research output: Contribution to journalLetterResearchpeer-review

  2. The Problem of Same-Rater Bias

    Research output: Contribution to journalLetterResearchpeer-review

  3. Parent Training for Preschool ADHD in Routine, Specialist Care: A Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effectiveness of cognitive remediation in the ultra-high risk state for psychosis

    Research output: Contribution to journalLetterResearchpeer-review

  2. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reappraisal is an effective emotion regulation strategy in children with Tourette syndrome and ADHD

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The autism diagnostic observation schedule: Patterns in individuals with anorexia nervosa

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objective: To investigate cardiometabolic effects and their predictors in youths with first-episode psychosis (FEP) treated with quetiapine-extended release (ER) versus aripiprazole. Method: Youths with FEP who were 12 to 17 years of age were randomized to quetiapine-ER or aripiprazole in the 12-week, double-blinded, Tolerability and Efficacy of Antipsychotics (TEA) trial. Primary outcome was change in body weight; secondary outcomes were changes in body mass index (BMI) and waist circumference (WC), blood pressure (BP), heart rate, and lipid and glucose metabolism parameters. Possible predictors of cardiometabolic changes were examined. Results: Altogether, 113 patients (schizophrenia-spectrum disorders = 93%; age [mean ± SD] = 15.7 ± 1.4 years; male participants = 30.1%) were randomized to quetiapine-ER (n = 55) or aripiprazole (n = 58). Quetiapine-ER led to significant increases in body weight (4.88 kg, 95% CI = 3.92−5.83, p < .0001), BMI z-score (0.43, 95% CI = 0.33−0.53, p < .0001), and WC z-score (0.97, CI = 0.7−1.23, p < .0001). Changes were significantly smaller with aripiprazole (all between-group p values <.0001): body weight: 1.97 kg (CI = 0.97−2.97, p = .0001), BMI z-score: 0.10 (CI = −0.01 to 0.20, p = .0646), and WC z-score: 0.18 (CI = −0.09 to 0.45, p = .1968). Lipid and glucose metabolism parameters increased significantly at week 4 and week 12 only with quetiapine-ER (p range = 0.0001−0.037). Quetiapine-ER was associated with an increased occurrence of obesity, elevated blood lipids and hyperinsulinemia (p range = 0.004−0.039). Early weight gain, obesity, or type 2 diabetes in the family significantly predicted weight and BMI gain at week 12. Conclusion: In youths with FEP, quetiapine-ER was associated with significantly greater weight gain and adverse changes in metabolic outcomes than was aripiprazole. Early weight gain must be addressed and family lifestyle factors taken into consideration when treating youths with antipsychotics. Clinical trial registration information: Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA); https://clinicaltrials.gov; NCT01119014.

Original languageEnglish
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume58
Issue number11
Pages (from-to)1062-1078
Number of pages17
ISSN0890-8567
DOIs
Publication statusPublished - Nov 2019

Bibliographical note

Copyright © 2019 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

    Research areas

  • antipsychotics, first episode psychosis, glucose, lipids, predictors

ID: 56819580